Included in the formulation
АТХ:N.07.X.X.08 Tafamidis
Pharmacodynamics:Selectively binds two thyroxine-binding regions of the tetrameric form of the protein transthyretin, preventing its dissociation and decomposition into water-soluble monomers. This slows down amyloidogenesis.
Pharmacokinetics:After oral administration, up to 90% is absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is achieved after 1.75 hours. The connection with plasma proteins is 99.9%.
Metabolism in the liver by glucuronation.
The half-life is 59 hours. Elimination by the kidneys and with feces.
Indications:It is used for treatment of Alzheimer's disease, family transthyretinovoy amyloid neuropathy.
VI.G30-G32.G30 Alzheimer's disease
IV.E70-E90.E85.1 Neuropathic hereditary family amyloidosis
Contraindications:Age to 18 years, pregnancy and lactation, individual intolerance.
Carefully:Hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Inside, 20 mg once a day.
The highest daily dose: 20 mg.
The highest single dose: 20 mg.
Side effects:Digestive system: pain in the upper abdomen, diarrhea.
urinary system: urinary tract infections.
Reproductive system: vaginal infections.
Allergic reactions.
Overdose:Headache, myalgia, insomnia.
Treatment is symptomatic.
Interaction:Clinically significant interactions are not described.
Special instructions:During treatment and a month after the end of taking the drug it is recommended to use reliable methods of contraception.